AstraZeneca Makes European IO Debut With Imfinzi Lung Cancer Approval

Imfinzi will be the fourth PD-1/L1 inhibitor approved for lung cancer in Europe, but AstraZeneca could carve out a niche by being indicated for sequential use following chemoradiation.

Business niche market and specializing in a smaller opportunity as an individual dart going a different way as a metaphor for strategic planning as a 3D illustration.
Late to market but targeting a new niche: Imfinzi • Source: Shutterstock

Having received the green light from the European Commission, AstraZeneca PLC will launch its checkpoint inhibitor Imfinzi in its first indication for the European markets. Approved to treat locally advanced, unresectable non-small cell lung cancer following chemotherapy and radiation therapy, the treatment setting for Imfinzi (durvalumab) is differentiated from that of already approved products in its class, which should enable it to gain a decent-sized foothold even against strong competition.

Already on the market in Europe for various non-small cell lung cancer indications are Bristol-Myers Squibb Co.’s Opdivo (nivolumab)...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip